| Literature DB >> 34208592 |
Javier Ramón1,2, Ferran Vila-Julià1,2, David Molina-Granada1,2, Miguel Molina-Berenguer1,2, Maria Jesús Melià1,2, Elena García-Arumí1,2, Javier Torres-Torronteras1,2, Yolanda Cámara1,2, Ramon Martí1,2.
Abstract
Mitochondrial DNA depletion and multiple deletions syndromes (MDDS) constitute a group of mitochondrial diseases defined by dysfunctional mitochondrial DNA (mtDNA) replication and maintenance. As is the case for many other mitochondrial diseases, the options for the treatment of these disorders are rather limited today. Some aggressive treatments such as liver transplantation or allogeneic stem cell transplantation are among the few available options for patients with some forms of MDDS. However, in recent years, significant advances in our knowledge of the biochemical pathomechanisms accounting for dysfunctional mtDNA replication have been achieved, which has opened new prospects for the treatment of these often fatal diseases. Current strategies under investigation to treat MDDS range from small molecule substrate enhancement approaches to more complex treatments, such as lentiviral or adenoassociated vector-mediated gene therapy. Some of these experimental therapies have already reached the clinical phase with very promising results, however, they are hampered by the fact that these are all rare disorders and so the patient recruitment potential for clinical trials is very limited.Entities:
Keywords: depletion; gene therapy; mitochondria; mtDNA; multiple deletions; nucleoside; replication; therapy
Year: 2021 PMID: 34208592 DOI: 10.3390/ijms22126447
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923